Biotech Values

[mcbio]

Celldex Therapeutics Inc. (NASDAQ: CLDX). This biopharmaceutical company focuses on the development, manufacture and commercialization of novel therapeutics for human health care, primarily in the United States. The stock closed yesterday at $7.21, and Cantor Fitzgerald has a $9 price target. Now $13 target

I've done quite well with CLDX so far. Been debating whether or not I should at least take some chips off the table but have yet to do so. There are plenty of potential catalysts in 2013, including a potential partner for 011, first controlled data for rindo (in combo w/Avastin), first clinical data for CDX-1135, etc. Of course, if CLDX raises money soon, I expect shares to retreat as it would signal no partner on the horizon for 011. I'm continuing to hold in full for now though. (I'd be happy to sell my shares in full at that $13 Cantor price target.)